GlassScriptPhysician profile
Husna R Baksh
NPI 1740396092
$1,419.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $149 · 2021: $52.78 · 2023: $72.59 · 2024: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540 · Travel and Lodging: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.10 |
| Travel and Lodging | $265.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $571.53 | 2024 | |
| Amgen INC. | $177.07 | 2019-2023 | Evenity, Prolia |
| Novo Nordisk INC | $134.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.83 | 2019-2023 | Jardiance |
| Inspire Medical Systems, INC. | $122.69 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $71.35 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Phadia US INC. | $47.95 | 2019-2024 | Immunocap |
| Lilly USA, LLC | $34.02 | 2019-2020 | |
| Allergan, INC. | $33.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.67 | 2019-2020 | |
| Dynavax Technologies Corporation | $21.31 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.27 | 2020 | |
| Gilead Sciences, INC. | $18.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.18 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husna Baksh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.